依库珠单抗在阵发性睡眠性血红蛋白尿症中的模型引导精准给药
本研究在27例阵发性睡眠性血红蛋白尿症患者中开展前瞻性观察性药代动力学研究,并整合非典型溶血性尿毒症综合征患者数据建立群体药代/药效模型。模型预测标准负荷剂量下仅52.0%患者第7天补体抑制充分,而基于体重的负荷剂量可使99.9%患者达标且不增加治疗成本。
要点
- 标准负荷剂量下仅52.0%阵发性睡眠性血红蛋白尿症患者第7天补体抑制充分。
- 基于体重的负荷剂量可使99.9%患者补体抑制充分且不增加治疗成本。
- 治疗药物监测可支持将给药间隔延长至4周而不显著增加累积药物用量。
核心结论
- 依库珠单抗在阵发性睡眠性血红蛋白尿症与非典型溶血性尿毒症综合征患者中药代动力学相似,但前者个体内变异更小。
- 替代给药方案可在疗效和患者便利性方面改善治疗。
研究设计与样本
- 前瞻性观察性药代动力学研究纳入27例阵发性睡眠性血红蛋白尿症患者,并整合既往非典型溶血性尿毒症综合征患者的药代/药效数据。
- 建立群体药代/药效模型,用于探索替代和个体化给药方案。
主要发现
- 二室模型伴平行线性和非线性消除最佳描述数据。
- 阵发性睡眠性血红蛋白尿症患者未观察到清除率的个体内变异,与非典型溶血性尿毒症综合征患者不同。
- 抑制性Emax模型描述血浆浓度与补体活性之间的关系。
- 模型预测标准负荷剂量下仅52.0%阵发性睡眠性血红蛋白尿症患者第7天补体抑制充分,而基于体重的负荷剂量下为99.9%,且不增加治疗成本。
- 开发了每4周给药方案,治疗药物监测可支持将给药间隔延长至4周而不显著增加累积药物用量。
关键数值与推荐
- 标准负荷剂量下第7天补体抑制充分患者比例为52.0%。
- 基于体重的负荷剂量下第7天补体抑制充分患者比例为99.9%。
- 基于体重的负荷剂量不增加治疗成本。
临床怎么用
- 可考虑基于体重的负荷剂量以提高阵发性睡眠性血红蛋白尿症患者第7天补体抑制达标率。
- 治疗药物监测可用于支持将给药间隔延长至4周而不显著增加累积药物用量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: Eculizumab is an expensive therapeutic monoclonal antibody inhibiting complement C5 and approved for various indications, including the rare disease paroxysmal nocturnal hemoglobinuria. Eculizumab is administered in a "one-dose-fits-all" dosing paradigm in adults, which is inflexible and suboptimal in some patients. Therefore, the aim of this study was to develop alternative dosing regimens that may improve patient friendliness or improve cost effectiveness. METHODS: A prospective observational pharmacokinetic study was conducted in 27 patients with paroxysmal nocturnal hemoglobinuria. The dataset was enriched with pharmacokinetic and pharmacodynamic data of a previous study of patients with atypical hemolytic uremic syndrome. A population pharmacokinetic/pharmacodynamic model was developed and this model was used to explore alternative and individualized dosing regimens. RESULTS: A two-compartment model with parallel linear and non-linear elimination best described the data. No intra-individual variability in clearance could be observed for patients with paroxysmal nocturnal hemoglobinuria in contrast to patients with atypical hemolytic uremic syndrome. An inhibitory Emax model described the relationship between plasma concentrations and complement activity. We predicted that only 52.0% of patients with paroxysmal nocturnal hemoglobinuria have adequate complement inhibition on day 7 with the standard loading dose, compared with 99.9% of the patients with an alternative weight-based loading dose, without an increase in treatment costs. A 4-weekly dosing regimen was developed and therapeutic drug monitoring will enable interval prolongation to 4 weeks without relevant increases in cumulative drug use compared to the approved dose. CONCLUSIONS: The pharmacokinetics of eculizumab are similar in patients with atypical hemolytic uremic syndrome and patients with paroxysmal nocturnal hemoglobinuria, yet less variable in patients with paroxysmal nocturnal hemoglobinuria. Alternative dosing regimens can improve treatment in terms of efficacy and patient friendliness. CLINICAL TRIAL REGISTRATION: ClincialTrials.gov identifier: NCT04079257.
引用
- Ter Avest M, Langemeijer SMC, van den Heuvel LPWJ, et al. Model-Informed Precision Dosing of Eculizumab in Patients with Paroxysmal Nocturnal Hemoglobinuria. Clin Pharmacokinet. 2025. PMID: 40560515. doi:10.1007/s40262-025-01536-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。